Barriga AG, Mercado GNF, Arumir EC

Language: Spanish
References: 33
Page: 90-98
PDF size: 86.91 Kb.

ABSTRACT

Objective. In vitro evaluation of 10 antimicrobial agents: amikacin, cefalexin, ceftibuten, cefuroxime, ciprofloxacin, gemifloxacin, netilmicin, moxifloxacin, levofloxacin, trimetoprim-sulfametoxazol, against Gram negative bacteria in outpatients with non-complicated urinary tract infections.
Material and methods. Prospective study of antimicrobial sensitivity of 1,200 Gram negative bacteria isolated from the same number of patients of both sexes and all ages, with non complicated urinary tract infections, using the plate microdilution technique to determine MIC 50 and 90, and percents of susceptibility.
Results. Most of isolates correspond to Escherichia coli: 638 (53.2%), followed by Klebsiella spp.: 166 (13.9%), Proteus spp.: 110 (9.1%), Morganella morganii: 84 (7.0%), Serratia spp.: 84 (7.0%), Enterobacter spp.: 66 (5.5%), and Citrobacter spp.: 52 (4.38%). The most active antimicrobials in terms of susceptibility and CIM 50 and 90 were ceftibuten and netilmicin. The other studied antibiotics show a very poor activity that varied according the isolated organism.
Conclusions. In view of the results of this in vitro study, ceftibuten and netilmicin were the most active antimicrobials against the Gram negative etiological agents of the non-complicated urinary tract infections.

REFERENCES

1. Acharya VN, Jadav SK. “Urinary tract infection: current status”. Journ Postg Med [serial online] 1980; 26 (2) 95-98

2. Orenstein R, Wong ES. “Urinary tract infections in adults”. Am Fam Phy 1999; 59, 5.

3. Vigoa AV. “Infección urinaria en el adulto”. Rev Cub Med 1998; 34 (2): 1-8

4. Wagenlehner FM, Naber KG. “Treatment of bacterial urinary tract infections: present and future”. Eur Urol 2006; 49: 235-244

5. Correia C, Costas E, Peres A, Alves M, Pombo G, Estevinho L. “Etiologia das infecções do tracto urinário e sua suceptibilidade aos Antimicrobianos”. Acta. Méd. Port. 2007; 20: 543-549

6. Arredondo GJL, Soriano BD, Solórzano ST, Arbo SA, Coria JR. “Etiología y tratamiento de infecciones de vías urinarias en niños”. Rev. Enf. Infec. en Pediatría 2006; Vol. XIX 76: 100-106

7. Aguirre AH, Plascencia HA, Rivera MC. Guerrero MB, Murillo NV. “Resistencia de Escherichia coli en infecciones de vías urinarias en pacientes pediátricos del Hospital Civil de Guadalajara Fray Antonio Alcalde”. Enf Inf Microbiol 2007; 27 (3): 83-87

8. Barragan A. I. A, Barriga A. G, Calderon F. F, Casasola G. J. I, Francolugo V. V.l A, Jamaica V. E, Medina O. H, MoralesM. J. G, Morfin O. R, Rodriguez G. L, Zavala T. I. G. 1er. Consenso Nacional sobre manejo Antimicrobiano de Infecciones de Vias Urinarias (IUVS) en el Adulto. Boletín Rev. Col. Mex. Urol.: 2005; 20 (2): 46-57.

9. Isenberg HP. Clinical Microbiology Procedures Handbook 2004. 2nd Edition, ASM Press. Washington, DC

10. Henry C. Isenberg, Update of the Clinical Microbiology Procedures Handbook 2007, 2nd Edition, ASM Press. Washington, DC.

11. Murray PP, Barron EJ, Jorgensen J, Pfaller M, Landry ML. Manual of Clinical Microbiology 2007. 9th Edition, ASM Press. Washington, DC

12. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. Eighteenth Informational Supplement 2008, M100-S18.

13. González PA. “Vigilancia de la resistencia a antimicrobianos”. Rev Chil Infectol 2002; 19 (2): 1-8

14. Marshall WF, Blair JE. “The cefalosporines”. Mayo Clin Proc 1999; 74: 187-195

15. Rivas KB, Rivas M A, Dávila EL, Rodríguez M. “Cefalosporinas de la Primera a la Cuarta Generación”. Rev Fac Med 2002; 25 (2): 3-18

16. Bedenic B, Topic M, Budimir A, Budimir M. “Urinary Bactericidal Activity of Oral Antibiotics against common urinary tract pathogens in an ex vivo Model”. Chemotherapy: 2006; 52: 293-297

17. Palomino J, Pachon J. “Aminoglucosidos”. Enf. Infec. Microbiol. Clin. 2003; 21 (2): 105-115

18. Barranco HE. “Aminoglucósidos”. Acta Médica 1998;8 (1): 48-53

19. Verbist L, Jacobs J, Hens K. “Comparative antimicrobial activity of Ceftibuten against multiply-resistant microorganism from Belgium”. Diagn Microbiol and Infect Dis. 1991; 14 (1): 53-61

20. Bhatnagar S., Chandra J. “Ceftibuten”. Indian Pediatrics: 1999: 36; 901-904

21. Maioli E, Marchese A, Roveta S, Cagnacci S, Cavallini F, Cassanolli C, Guaico L, Debbia EA. “In vitro activity of ceftibuten at sub-inhibitory concentrations in comparison with other antibiotics against respiratory and urinary tract pathogens”. J Chemother 2007; 19 (2): 152-160

22. Schito GC, Nicoletti G. “Susceptibility of respiratory and urinary tract pathogens to Ceftibuten and other comparative drugs: results of an Italian multicenter survey: the The Italian Ceftibuten Study Group”. J Chemother 1994; 6 (2): 92-98

23. Jones RN. “Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features”. Pediat Infec Dis J 1995; 14 (7): Supl. S77-S83

24. Guay DR. “Ceftibuten: a new expanded-spectrum oral cephalosporin”. Ann Pharmacother 1997; 31 (9): 1O22-1033

25. Sauer K, Rickard A. H, Davies G.D. “Biofilms and Biocomplexity: Microbe”, The News Magazine of the American Society for Microbiology. 2007, 2, 7, 347-353.

26. Jones RN, Bany AL. “Ceftibuten (7432-S, SCH 39720): Comparative antimicrobial activity against 4735 clinical isolates, beta lactamase stability and broth microdilution quality control guidelines”. European Jour. Clin Microb Infect. Dis.1988; 7 (6): 802-807

27. Meyers BR, Flirschman SZ. “Antimicrobial activity in vitro of Netilmicin and comparison with Sisomicin, Gentamicin and Tobramycin”. Antimicrob Agen Chemother 1977; 11 (1): 118-121

28. Fu KP, Neu HC. “In vitro study of netilmicin compared with other aminoglycosides”. Antimicrob Agen Chemother 1976,: 10 (3) 526-34.

29. Dagnra AY, Prince-David M, Hounkpati A. “Antimicrobial activity of ciprofloxacin and netilmicin compared to various antibiotics in Lome, Togo”. Sante 2001; 11 (1): 63-66

30. Braveny I, Voeckj, Machka K. “Antimicrobial activity of netilmicin in comparacion with gentamicin, sisomicina, tobramycin and amikacin and their resistance patterns”. Arzneimittelforschung: 1980; 30 (3), 491-5

31. Kabins SA, Nathan C, Cohen S. “In vitro comparison of netilmicin, a semi synthetic derivate of sisomicin, and four other aminoglycoside antibiotics”. Antimicrob Agents Chemother 1976; 10 (1): 139-145

32. Briedis DJ, Robson HG. “Comparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae”. Antimicrob Agents Chemother 1976; 10 (4): 592-597

33. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA. “Penetration of netilmicin in the lower respiratory tract after once-daily dosing”. Chest 1992; 101: 1028-103.